Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Word about Beetlebung Pharma

<< Previous

Bullboard Posts

Next >>

Comment by Lubb123on May 27, 2020 9:36pm

115 Views

Post# 31080858

RE:RE:Word about Beetlebung Pharma

Injection is easier to manage patient care. One injection (time released) will dose throughout a 24 hour period. In gas form it must be administered monitored by a Dr with a mechanical ventilator usually in a 20-30 minute session. Huge difference.

Once it is determined is NOx works on Covid symptoms the method of administering does not have to be approved.

Salzman is working on clinical testing for the injectable dosing.

I found the Salzman site quite thorough. Wondering what's in it for them.

Then heard they want to get into the Shroom business. That's a hot market these days! I've been piling on for three days.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project